Ordering workflow
Multi-state practice ordering: what changes per state
Crossing a state line changes three things at once, and they are decided by three different regulators: whether your supplier holds that state’s credential, what that state permits to be shipped in at all, and what the receiving practice must itself hold, keep or report. The agency issuing the supplier’s credential is not even consistent — in the states we have read it ranges from a board of pharmacy to a department of agriculture to a department of state health services.
What actually changes when you cross a state line?
Three separate things, decided by three different regulators, and they fail independently of each other.
The first is whether your supplier holds a credential in the destination state. The second is what that state permits to be shipped in at all, which is not the same question. The third is what the practice receiving the product must itself hold, keep or report.
A multi-state programme usually breaks at the seam between these rather than inside any one of them. A supplier can be impeccably licensed where it sits and unable to ship to your Colorado site. A state can permit the transaction and still require your practice to hold a permit nobody mentioned. Each layer is worked through below, in the order it will stop you.
Layer one: does your supplier hold that state's credential?
Federal registration does not answer this, and the agency that issues the credential is not even consistent.
Section 353b is a federal exemption from federal law. It preempts nothing at the state level, so a facility that satisfies it in full and holds nothing in the destination state is not compliant — it is federally clean and state-exposed. In every state we read in full and were able to verify, a state credential was required on top of the federal registration. Georgia is the single exception in our set, and only because we could not verify it either way.
The agency varies enough that "we're licensed" is not a checkable answer:
| State | Where the outsourcing facility's credential comes from |
|---|---|
| North Carolina | The Commissioner of Agriculture, under G.S. 106-140.1 — not the Board of Pharmacy |
| Texas | The Department of State Health Services, as a wholesale distribution licence "for each place of business" |
| California | The Board of Pharmacy, under BPC § 4129.2, with an annual on-site inspection reimbursed at the facility's expense |
| Florida | The Board of Pharmacy, as a nonresident sterile compounding permit |
| New York | The Education Department, as a nonresident establishment registration |
| Colorado | The Board of Pharmacy, as a nonresident 503B outsourcing facility registration |
| Arizona | The Board of Pharmacy, permitted as a drug manufacturer — Arizona has no outsourcing-facility category |
| New Jersey | Unsettled; no outsourcing-facility category exists, and the likely route runs through the Department of Health |
| Georgia | Unverified in our research |
The practical form of the question is therefore: which states do you hold a credential in, and which agency issued each one.
Layer two: what may be shipped into that state at all?
Some states answer this with a permit condition. At least one answers it with a prohibition.
Colorado's rules provide that "nonresident prescription drug outlets shall not distribute compounded products into Colorado," and that those registered there "may dispense compounded products and ship them into Colorado only pursuant to valid, patient-specific prescription orders," with a separate lane for Colorado-licensed veterinarians. For an out-of-state pharmacy shipping compounded office stock into Colorado, that is an express prohibition rather than silence.
California requires a nonresident pharmacy compounding sterile products for shipment into the state to hold a sterile compounding pharmacy licence, with annual on-site inspection at the pharmacy's own expense. Illinois conditions sterile office use on the pharmacy being registered as an outsourcing facility and licensed as an Illinois wholesale drug distributor. Arizona requires both an Arizona nonresident permit and a current equivalent licence in the home jurisdiction.
New York does something different again: its rules bind a registered nonresident establishment to New York's own pharmacy provisions for anything delivered into New York. The destination state's law follows the shipment by express adoption.
Layer three: what does the receiving practice owe?
This is the layer most often assumed away, and the answers are genuinely far apart.
Florida requires a health care clinic establishment permit where a business entity at one general physical location purchases prescription drugs — with an express carve-out for purchases made by a licensed practitioner under their own licence. Ohio treats a prescriber practice holding dangerous drugs as needing a terminal distributor licence, while naming possession of compounded preparations supplied by an Ohio-licensed outsourcing facility as a lower-risk activity that does not itself trigger licensure, and adding that "preparation of such medications in advance of administration requires licensure."
At the other end, Colorado attaches no permit, quantity cap, labelling duty, retention period or reporting duty to the receiving practice at all, and its statute affirmatively provides that a licensed health-care provider may obtain and administer compounded product supplied by a registered nonresident outsourcing facility. Texas reaches the same place by a different route: its statute exempts a practitioner, and its rules define a clinic as a facility "other than a physician's office."
Where do controlled substances change the picture?
Where a state registers the place rather than the person.
Louisiana provides that a practitioner's controlled-substance licence is valid anywhere in the state, but that "the procurement and possession of controlled substances shall require a separate CDS license for each such location where controlled substances are possessed." New Jersey exempts a prescriber's office from registration only where no controlled substances are administered, delivered or dispensed there and none are "contained in such office" — an exemption that ends the moment stock is on the premises.
For a practice adding sites, that is the difference between updating a record and obtaining a new registration before anything can be delivered.
What about the records each state expects?
Different periods, different holders, and mostly binding on the practice regardless of which pathway supplied it.
Among the states we read, Texas requires a practitioner to "maintain a record of each acquisition and each disposal of a dangerous drug for two years," inspectable at all reasonable hours with an inventory of stocks on hand. California requires a current inventory kept by every physician "who maintains a stock of dangerous drugs," preserved at least three years. New Jersey's controlled-substance records run two years or the professional board's period, whichever is longer. Louisiana requires five years of dispensing-registrant records with a quarterly physical inventory. Colorado, as above, imposes none on the practice.
The trap is assuming the longest one and calling it compliance. Several of these are inventory duties with inspection conditions attached, not filing periods.
Which of these answers has a date on it?
Arizona's, and it is imminent.
Arizona's current rule expressly permits a compounded preparation to be provided to a medical practitioner for administration, with a two-legend label reading "Not For Dispensing" and "For Office or Hospital Administration Only." That provision is in force through 4 September 2026. From 5 September 2026, amended rule R4-23-410(F) provides that a pharmacy or pharmacist "shall not provide a compounded pharmaceutical product to a pharmacy, medical practitioner, or other person unless the medical practitioner is a veterinarian."
Arizona permits compounded office stock only for veterinarians from that date; human office use is prohibited. Two details matter for a multi-state programme. The Board's own preamble frames the rewrite as an alignment exercise and never mentions removing human office use — the repeal is in the rule text, not the summary. And the same rulemaking left Arizona's nonresident and outsourcing-facility licensure layer untouched, so the outsourcing-facility route into Arizona does not close with it.
What is the same in every state?
Two federal things, and they are the ones worth building the programme around.
Section 353a's exemption attaches only where the drug is compounded for an identified individual patient on a valid prescription order. And section 353b regulates the facility, not its customer: nothing in the federal provision tells a prescriber's practice what it must hold, label, record or report, which is why layer three is a pure question of state law everywhere.
Everything else on this page is a state answer, and a state answer is only as current as the day someone read the rule.
What we could not establish
Four gaps, published rather than smoothed over, because a multi-state programme is exactly where a confident guess does damage.
Georgia's credential requirement for an outsourcing facility shipping in is unverified. New Jersey's registration category for one is unsettled. Florida's permit position for non-sterile office stock shipped in was not resolved. And whether a telehealth-only practice counts as a "practitioner's office" under Texas's office-use apparatus is a live question we did not settle, which matters because it is the fact pattern many multi-state operators actually have.
Each state's own rule text, citation and last-reviewed date is at office-use compounding by state. The credential checks that sit underneath all of this are at prescriber credentialing: what pharmacies verify, the sequence at opening an account with a compounding pharmacy, and the wider workflow at how clinics order compounded medications.
To have your state list checked against a supplier's actual credentials before you commit to a programme, you can apply for an account.